Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC 3.0RSC Advances

AI-guided prioritization of potential FAM171A2 ligands through pharmacophore-aware and receptor-based screening

  1. 1Department of Anesthesia, The Second Affiliated Hospital of Xi'an Jiaotong University 710004 China
  2. 2Department of Bioengineering, College of Life Science, Dalian Minzu University 116600 China

Abstract

FAM171A2 has recently emerged as a potential therapeutic target in Parkinson's disease because it selectively recognizes α-synuclein fibrils and promotes their neuronal uptake. However, ligand prioritization for this receptor remains challenging because of scarce known binders, the absence of an experimentally resolved ligand-bound structure and the requirement for blood–brain barrier permeability. Here, we established an AI-guided computational screening framework that integrates pharmacophore-aware retrieval, hierarchical receptor-based screening, blood–brain barrier permeability prediction and molecular dynamics-based assessment to prioritize potential FAM171A2 ligands. Starting from 1.41 million compounds, the workflow progressively narrowed the search space to two structurally representative candidates, E634-1386 and F707-2364. Both candidates showed more favorable in silico profiles than the reference blocker Bemcentinib across complementary computational assessments: E634-1386 achieved higher KarmaDock and CarsiDock scores, whereas F707-2364 yielded the most favorable AutoDock Vina score and MM/GBSA estimate. Molecular dynamics simulations further suggested stable predicted FAM171A2-bound complexes for both candidates, with lower complex RMSD, reduced radius of gyration and lower protein solvent-accessible surface area relative to Bemcentinib, while maintaining broadly similar residue-level flexibility patterns. Representative interaction analysis suggested that E634-1386 may rely more on polar contacts, whereas F707-2364 may engage the predicted binding region through broader hydrophobic complementarity. Together, these results prioritize E634-1386 and F707-2364 as computationally selected, experimentally testable FAM171A2 ligand candidates and provide a practical strategy for early-stage ligand prioritization against structurally challenging central nervous system targets.

Related

  1. A Pharmacophore-Based Virtual Screening Approach for the Discovery of Novel P2Y ₁₂ Receptor Ligands
    Peter H. Moons, Anne van der Schatte van der Schatte Olivier, Fabian Dey +7
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
  2. Integrated machine learning, pharmacophore screening, and structure-based computational approaches for the identification of novel JAK3 inhibitors
    Muhammad Yasir, Jinyoung Park, Eun-Taek Han +4
    Future Medicinal ChemistryPeer-reviewedLicence not statedFull textMedicinal chemistry & drug discoveryPMC
  3. Integrated Computational Design and Multistage Virtual Screening for the Prioritization of Putative USP5 Catalytic-Cleft Inhibitors
    Shivansh Sahni, Kian Hershberger, Yubin Ge +1
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
  4. Computational design and prioritization of database-absent small-molecule GLP-1 receptor agonist candidates from public bioactivity data
    JOGU MOHAN
    ChemRxivPreprintCC BYFull textGeneral chemistryChemRxiv
  5. Chemistry-informed non-covalent graphs and pharmacophore supervision for molecular property prediction
    Weiqi Zhang, Xilan Wang, Xin Wang +3
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
BibTeX
@article{yan2026aiguided,
  title = {{AI-guided prioritization of potential FAM171A2 ligands through pharmacophore-aware and receptor-based screening}},
  author = {Baihui Yan and Yang Lu and Yanni Tong and Shaolong Lin and Wei Li},
  journal = {RSC Advances},
  year = {2026},
  month = nov,
  doi = {10.1039/d6ra07609b},
  url = {https://doi.org/10.1039/d6ra07609b},
  note = {CC BY-NC 3.0},
}
RIS
TY  - JOUR
TI  - AI-guided prioritization of potential FAM171A2 ligands through pharmacophore-aware and receptor-based screening
AU  - Baihui Yan
AU  - Yang Lu
AU  - Yanni Tong
AU  - Shaolong Lin
AU  - Wei Li
PY  - 2026
DA  - 2026/11/12
JO  - RSC Advances
DO  - 10.1039/d6ra07609b
UR  - https://doi.org/10.1039/d6ra07609b
AB  - FAM171A2 has recently emerged as a potential therapeutic target in Parkinson's disease because it selectively recognizes α-synuclein fibrils and promotes their neuronal uptake. However, ligand prioritization for this receptor remains challenging because of scarce known binders, the absence of an experimentally resolved ligand-bound structure and the requirement for blood–brain barrier permeability. Here, we established an AI-guided computational screening framework that integrates pharmacophore-aware retrieval, hierarchical receptor-based screening, blood–brain barrier permeability prediction and molecular dynamics-based assessment to prioritize potential FAM171A2 ligands. Starting from 1.41 million compounds, the workflow progressively narrowed the search space to two structurally representative candidates, E634-1386 and F707-2364. Both candidates showed more favorable in silico profiles than the reference blocker Bemcentinib across complementary computational assessments: E634-1386 achieved higher KarmaDock and CarsiDock scores, whereas F707-2364 yielded the most favorable AutoDock Vina score and MM/GBSA estimate. Molecular dynamics simulations further suggested stable predicted FAM171A2-bound complexes for both candidates, with lower complex RMSD, reduced radius of gyration and lower protein solvent-accessible surface area relative to Bemcentinib, while maintaining broadly similar residue-level flexibility patterns. Representative interaction analysis suggested that E634-1386 may rely more on polar contacts, whereas F707-2364 may engage the predicted binding region through broader hydrophobic complementarity. Together, these results prioritize E634-1386 and F707-2364 as computationally selected, experimentally testable FAM171A2 ligand candidates and provide a practical strategy for early-stage ligand prioritization against structurally challenging central nervous system targets.
SN  - 2046-2069
ER  -